Melanotan I
Melanotan I is supplied as a melanocortin MC1R-receptor agonist for pigmentation-pathway research in cell and tissue models. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
Melanotan I in research
Melanotan I is supplied as a melanocortin MC1R-receptor agonist for pigmentation-pathway research in cell and tissue models.
General RUO catalog item for documented laboratory workflows.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for Melanotan I before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
No supplier listing text is on file yet for this item.
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
Human data is limited. Afamelanotide, related to Melanotan I, has regulatory approval in a narrow dermatologic indication; Melanotan II has no such approval and limited controlled human data, alongside documented safety concerns.
Melanocortin-receptor research has studied pigmentation pathways and related signaling in models.
Melanotan II is widely discussed in tanning and community forums, where reports of side effects are also common. These are unverified anecdotal reports, not controlled findings, and not BioRegen claims.
Melanotan II is not FDA-approved and has been the subject of consumer-safety warnings. BioRegen supplies these melanocortin reference materials strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about Melanotan I
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
Both citations below are about afamelanotide, a closely related melanocortin compound with its own separate clinical-trial history for a rare skin condition. BioRegen's own Melanotan I research overview is explicit that this citation trail belongs to that related clinical compound, not to Melanotan I itself, and that the research peptide has a far thinner evidence base of its own.
- Langendonk JG, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. https://doi.org/10.1056/NEJMoa1411481
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. J Drugs Dermatol. https://doi.org/10.36849/JDD.5526